The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
The global HIV Antiretroviral Drug market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
North American market for HIV Antiretroviral Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
Asia-Pacific market for HIV Antiretroviral Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
Highlights
The global market for HIV Antiretroviral Drug in Hospital Pharmacies is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The major global companies of HIV Antiretroviral Drug include ViiV Healthcare(GlaxoSmithKline), Gilead Sciences, AbbVie Inc., Merck & Co, GSK, Bristol-Myers Squibb Company, Theratechnologies Inc., Roche Holding AG and Teva Pharmaceuticals, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
Considering the economic change due to COVID-19, Nucleoside Reverse Transcriptase Inhibitors, which accounted for % of the global market of HIV Antiretroviral Drug in 2021, is expected to reach US$ million by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for HIV Antiretroviral Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HIV Antiretroviral Drug.
The HIV Antiretroviral Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global HIV Antiretroviral Drug market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the HIV Antiretroviral Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- ViiV Healthcare(GlaxoSmithKline)
- Gilead Sciences
- AbbVie Inc.
- Merck & Co
- GSK
- Bristol-Myers Squibb Company
- Theratechnologies Inc.
- Roche Holding AG
- Teva Pharmaceuticals
- Pfizer
- Frontier Biotechnologies
- Shionogi
- Julphar Bangladesh
- Mylan Pharmaceuticals Inc.
- Genentech, Inc.
- Boehringer Ingelheim
- Cipla
- MSD
- Abbott
- Johnson & Johnson
- Biocon Limited
- Affine Formulations Limited
- IPCA Laboratories
- Natco Pharma
- Beacon Pharmaceuticals
Product Type Insights
Global markets are presented by HIV Antiretroviral Drug type, along with growth forecasts through 2028. Estimates on revenue are based on the price in the supply chain at which the HIV Antiretroviral Drug are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
HIV Antiretroviral Drug segment by Type
- Nucleoside Reverse Transcriptase Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Fusion Inhibitors
- Others
Application Insights
This report has provided the market size (revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the HIV Antiretroviral Drug market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the HIV Antiretroviral Drug market.
HIV Antiretroviral Drug Segment by Application
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia)
- Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
- Latin America (Mexico, Brazil, Argentina, Colombia)
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the HIV Antiretroviral Drug market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
- This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV Antiretroviral Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
- This report will help stakeholders to understand the global industry status and trends of HIV Antiretroviral Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
- This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
- This report stays updated with novel technology integration, features, and the latest developments in the market
- This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the HIV Antiretroviral Drug industry.
- This report helps stakeholders to gain insights into which regions to target globally
- This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV Antiretroviral Drug.
- This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of HIV Antiretroviral Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global HIV Antiretroviral Drug Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Nucleoside Reverse Transcriptase Inhibitors
1.2.3 Non-Nucleoside Reverse Transcriptase Inhibitors
1.2.4 Protease Inhibitors
1.2.5 Fusion Inhibitors
1.2.6 Others
1.3 Market by Application
1.3.1 Global HIV Antiretroviral Drug Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global HIV Antiretroviral Drug Market Perspective (2017-2028)
2.2 HIV Antiretroviral Drug Growth Trends by Region
2.2.1 HIV Antiretroviral Drug Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 HIV Antiretroviral Drug Historic Market Size by Region (2017-2022)
2.2.3 HIV Antiretroviral Drug Forecasted Market Size by Region (2023-2028)
2.3 HIV Antiretroviral Drug Market Dynamics
2.3.1 HIV Antiretroviral Drug Industry Trends
2.3.2 HIV Antiretroviral Drug Market Drivers
2.3.3 HIV Antiretroviral Drug Market Challenges
2.3.4 HIV Antiretroviral Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top HIV Antiretroviral Drug Players by Revenue
3.1.1 Global Top HIV Antiretroviral Drug Players by Revenue (2017-2022)
3.1.2 Global HIV Antiretroviral Drug Revenue Market Share by Players (2017-2022)
3.2 Global HIV Antiretroviral Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by HIV Antiretroviral Drug Revenue
3.4 Global HIV Antiretroviral Drug Market Concentration Ratio
3.4.1 Global HIV Antiretroviral Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by HIV Antiretroviral Drug Revenue in 2021
3.5 HIV Antiretroviral Drug Key Players Head office and Area Served
3.6 Key Players HIV Antiretroviral Drug Product Solution and Service
3.7 Date of Enter into HIV Antiretroviral Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 HIV Antiretroviral Drug Breakdown Data by Type
4.1 Global HIV Antiretroviral Drug Historic Market Size by Type (2017-2022)
4.2 Global HIV Antiretroviral Drug Forecasted Market Size by Type (2023-2028)
5 HIV Antiretroviral Drug Breakdown Data by Application
5.1 Global HIV Antiretroviral Drug Historic Market Size by Application (2017-2022)
5.2 Global HIV Antiretroviral Drug Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America HIV Antiretroviral Drug Market Size (2017-2028)
6.2 North America HIV Antiretroviral Drug Market Size by Country (2017-2022)
6.3 North America HIV Antiretroviral Drug Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe HIV Antiretroviral Drug Market Size (2017-2028)
7.2 Europe HIV Antiretroviral Drug Market Size by Country (2017-2022)
7.3 Europe HIV Antiretroviral Drug Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific HIV Antiretroviral Drug Market Size (2017-2028)
8.2 Asia-Pacific HIV Antiretroviral Drug Market Size by Country (2017-2022)
8.3 Asia-Pacific HIV Antiretroviral Drug Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America HIV Antiretroviral Drug Market Size (2017-2028)
9.2 Latin America HIV Antiretroviral Drug Market Size by Country (2017-2022)
9.3 Latin America HIV Antiretroviral Drug Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa HIV Antiretroviral Drug Market Size (2017-2028)
10.2 Middle East & Africa HIV Antiretroviral Drug Market Size by Country (2017-2022)
10.3 Middle East & Africa HIV Antiretroviral Drug Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 ViiV Healthcare(GlaxoSmithKline)
11.1.1 ViiV Healthcare(GlaxoSmithKline) Company Detail
11.1.2 ViiV Healthcare(GlaxoSmithKline) Business Overview
11.1.3 ViiV Healthcare(GlaxoSmithKline) HIV Antiretroviral Drug Introduction
11.1.4 ViiV Healthcare(GlaxoSmithKline) Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.1.5 ViiV Healthcare(GlaxoSmithKline) Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Detail
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences HIV Antiretroviral Drug Introduction
11.2.4 Gilead Sciences Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.2.5 Gilead Sciences Recent Development
11.3 AbbVie Inc.
11.3.1 AbbVie Inc. Company Detail
11.3.2 AbbVie Inc. Business Overview
11.3.3 AbbVie Inc. HIV Antiretroviral Drug Introduction
11.3.4 AbbVie Inc. Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.3.5 AbbVie Inc. Recent Development
11.4 Merck & Co
11.4.1 Merck & Co Company Detail
11.4.2 Merck & Co Business Overview
11.4.3 Merck & Co HIV Antiretroviral Drug Introduction
11.4.4 Merck & Co Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.4.5 Merck & Co Recent Development
11.5 GSK
11.5.1 GSK Company Detail
11.5.2 GSK Business Overview
11.5.3 GSK HIV Antiretroviral Drug Introduction
11.5.4 GSK Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.5.5 GSK Recent Development
11.6 Bristol-Myers Squibb Company
11.6.1 Bristol-Myers Squibb Company Company Detail
11.6.2 Bristol-Myers Squibb Company Business Overview
11.6.3 Bristol-Myers Squibb Company HIV Antiretroviral Drug Introduction
11.6.4 Bristol-Myers Squibb Company Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.6.5 Bristol-Myers Squibb Company Recent Development
11.7 Theratechnologies Inc.
11.7.1 Theratechnologies Inc. Company Detail
11.7.2 Theratechnologies Inc. Business Overview
11.7.3 Theratechnologies Inc. HIV Antiretroviral Drug Introduction
11.7.4 Theratechnologies Inc. Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.7.5 Theratechnologies Inc. Recent Development
11.8 Roche Holding AG
11.8.1 Roche Holding AG Company Detail
11.8.2 Roche Holding AG Business Overview
11.8.3 Roche Holding AG HIV Antiretroviral Drug Introduction
11.8.4 Roche Holding AG Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.8.5 Roche Holding AG Recent Development
11.9 Teva Pharmaceuticals
11.9.1 Teva Pharmaceuticals Company Detail
11.9.2 Teva Pharmaceuticals Business Overview
11.9.3 Teva Pharmaceuticals HIV Antiretroviral Drug Introduction
11.9.4 Teva Pharmaceuticals Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.9.5 Teva Pharmaceuticals Recent Development
11.10 Pfizer
11.10.1 Pfizer Company Detail
11.10.2 Pfizer Business Overview
11.10.3 Pfizer HIV Antiretroviral Drug Introduction
11.10.4 Pfizer Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.10.5 Pfizer Recent Development
11.11 Frontier Biotechnologies
11.11.1 Frontier Biotechnologies Company Detail
11.11.2 Frontier Biotechnologies Business Overview
11.11.3 Frontier Biotechnologies HIV Antiretroviral Drug Introduction
11.11.4 Frontier Biotechnologies Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.11.5 Frontier Biotechnologies Recent Development
11.12 Shionogi
11.12.1 Shionogi Company Detail
11.12.2 Shionogi Business Overview
11.12.3 Shionogi HIV Antiretroviral Drug Introduction
11.12.4 Shionogi Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.12.5 Shionogi Recent Development
11.13 Julphar Bangladesh
11.13.1 Julphar Bangladesh Company Detail
11.13.2 Julphar Bangladesh Business Overview
11.13.3 Julphar Bangladesh HIV Antiretroviral Drug Introduction
11.13.4 Julphar Bangladesh Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.13.5 Julphar Bangladesh Recent Development
11.14 Mylan Pharmaceuticals Inc.
11.14.1 Mylan Pharmaceuticals Inc. Company Detail
11.14.2 Mylan Pharmaceuticals Inc. Business Overview
11.14.3 Mylan Pharmaceuticals Inc. HIV Antiretroviral Drug Introduction
11.14.4 Mylan Pharmaceuticals Inc. Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.14.5 Mylan Pharmaceuticals Inc. Recent Development
11.15 Genentech, Inc.
11.15.1 Genentech, Inc. Company Detail
11.15.2 Genentech, Inc. Business Overview
11.15.3 Genentech, Inc. HIV Antiretroviral Drug Introduction
11.15.4 Genentech, Inc. Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.15.5 Genentech, Inc. Recent Development
11.16 Boehringer Ingelheim
11.16.1 Boehringer Ingelheim Company Detail
11.16.2 Boehringer Ingelheim Business Overview
11.16.3 Boehringer Ingelheim HIV Antiretroviral Drug Introduction
11.16.4 Boehringer Ingelheim Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.16.5 Boehringer Ingelheim Recent Development
11.17 Cipla
11.17.1 Cipla Company Detail
11.17.2 Cipla Business Overview
11.17.3 Cipla HIV Antiretroviral Drug Introduction
11.17.4 Cipla Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.17.5 Cipla Recent Development
11.18 MSD
11.18.1 MSD Company Detail
11.18.2 MSD Business Overview
11.18.3 MSD HIV Antiretroviral Drug Introduction
11.18.4 MSD Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.18.5 MSD Recent Development
11.19 Abbott
11.19.1 Abbott Company Detail
11.19.2 Abbott Business Overview
11.19.3 Abbott HIV Antiretroviral Drug Introduction
11.19.4 Abbott Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.19.5 Abbott Recent Development
11.20 Johnson & Johnson
11.20.1 Johnson & Johnson Company Detail
11.20.2 Johnson & Johnson Business Overview
11.20.3 Johnson & Johnson HIV Antiretroviral Drug Introduction
11.20.4 Johnson & Johnson Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.20.5 Johnson & Johnson Recent Development
11.21 Biocon Limited
11.21.1 Biocon Limited Company Detail
11.21.2 Biocon Limited Business Overview
11.21.3 Biocon Limited HIV Antiretroviral Drug Introduction
11.21.4 Biocon Limited Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.21.5 Biocon Limited Recent Development
11.22 Affine Formulations Limited
11.22.1 Affine Formulations Limited Company Detail
11.22.2 Affine Formulations Limited Business Overview
11.22.3 Affine Formulations Limited HIV Antiretroviral Drug Introduction
11.22.4 Affine Formulations Limited Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.22.5 Affine Formulations Limited Recent Development
11.23 IPCA Laboratories
11.23.1 IPCA Laboratories Company Detail
11.23.2 IPCA Laboratories Business Overview
11.23.3 IPCA Laboratories HIV Antiretroviral Drug Introduction
11.23.4 IPCA Laboratories Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.23.5 IPCA Laboratories Recent Development
11.24 Natco Pharma
11.24.1 Natco Pharma Company Detail
11.24.2 Natco Pharma Business Overview
11.24.3 Natco Pharma HIV Antiretroviral Drug Introduction
11.24.4 Natco Pharma Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.24.5 Natco Pharma Recent Development
11.25 Beacon Pharmaceuticals
11.25.1 Beacon Pharmaceuticals Company Detail
11.25.2 Beacon Pharmaceuticals Business Overview
11.25.3 Beacon Pharmaceuticals HIV Antiretroviral Drug Introduction
11.25.4 Beacon Pharmaceuticals Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.25.5 Beacon Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
List of Tables
Table 1. Global HIV Antiretroviral Drug Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Nucleoside Reverse Transcriptase Inhibitors
Table 3. Key Players of Non-Nucleoside Reverse Transcriptase Inhibitors
Table 4. Key Players of Protease Inhibitors
Table 5. Key Players of Fusion Inhibitors
Table 6. Key Players of Others
Table 7. Global HIV Antiretroviral Drug Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global HIV Antiretroviral Drug Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global HIV Antiretroviral Drug Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global HIV Antiretroviral Drug Market Share by Region (2017-2022)
Table 11. Global HIV Antiretroviral Drug Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global HIV Antiretroviral Drug Market Share by Region (2023-2028)
Table 13. HIV Antiretroviral Drug Market Trends
Table 14. HIV Antiretroviral Drug Market Drivers
Table 15. HIV Antiretroviral Drug Market Challenges
Table 16. HIV Antiretroviral Drug Market Restraints
Table 17. Global HIV Antiretroviral Drug Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global HIV Antiretroviral Drug Market Share by Players (2017-2022)
Table 19. Global Top HIV Antiretroviral Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HIV Antiretroviral Drug as of 2021)
Table 20. Ranking of Global Top HIV Antiretroviral Drug Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by HIV Antiretroviral Drug Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players HIV Antiretroviral Drug Product Solution and Service
Table 24. Date of Enter into HIV Antiretroviral Drug Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global HIV Antiretroviral Drug Market Size by Type (2017-2022) & (US$ Million)
Table 27. Global HIV Antiretroviral Drug Revenue Market Share by Type (2017-2022)
Table 28. Global HIV Antiretroviral Drug Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 29. Global HIV Antiretroviral Drug Revenue Market Share by Type (2023-2028)
Table 30. Global HIV Antiretroviral Drug Market Size by Application (2017-2022) & (US$ Million)
Table 31. Global HIV Antiretroviral Drug Revenue Market Share by Application (2017-2022)
Table 32. Global HIV Antiretroviral Drug Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 33. Global HIV Antiretroviral Drug Revenue Market Share by Application (2023-2028)
Table 34. North America HIV Antiretroviral Drug Market Size by Country (2017-2022) & (US$ Million)
Table 35. North America HIV Antiretroviral Drug Market Size by Country (2023-2028) & (US$ Million)
Table 36. Europe HIV Antiretroviral Drug Market Size by Country (2017-2022) & (US$ Million)
Table 37. Europe HIV Antiretroviral Drug Market Size by Country (2023-2028) & (US$ Million)
Table 38. Asia-Pacific HIV Antiretroviral Drug Market Size by Region (2017-2022) & (US$ Million)
Table 39. Asia-Pacific HIV Antiretroviral Drug Market Size by Region (2023-2028) & (US$ Million)
Table 40. Latin America HIV Antiretroviral Drug Market Size by Country (2017-2022) & (US$ Million)
Table 41. Latin America HIV Antiretroviral Drug Market Size by Country (2023-2028) & (US$ Million)
Table 42. Middle East & Africa HIV Antiretroviral Drug Market Size by Country (2017-2022) & (US$ Million)
Table 43. Middle East & Africa HIV Antiretroviral Drug Market Size by Country (2023-2028) & (US$ Million)
Table 44. ViiV Healthcare(GlaxoSmithKline) Company Detail
Table 45. ViiV Healthcare(GlaxoSmithKline) Business Overview
Table 46. ViiV Healthcare(GlaxoSmithKline) HIV Antiretroviral Drug Product
Table 47. ViiV Healthcare(GlaxoSmithKline) Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 48. ViiV Healthcare(GlaxoSmithKline) Recent Development
Table 49. Gilead Sciences Company Detail
Table 50. Gilead Sciences Business Overview
Table 51. Gilead Sciences HIV Antiretroviral Drug Product
Table 52. Gilead Sciences Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 53. Gilead Sciences Recent Development
Table 54. AbbVie Inc. Company Detail
Table 55. AbbVie Inc. Business Overview
Table 56. AbbVie Inc. HIV Antiretroviral Drug Product
Table 57. AbbVie Inc. Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 58. AbbVie Inc. Recent Development
Table 59. Merck & Co Company Detail
Table 60. Merck & Co Business Overview
Table 61. Merck & Co HIV Antiretroviral Drug Product
Table 62. Merck & Co Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 63. Merck & Co Recent Development
Table 64. GSK Company Detail
Table 65. GSK Business Overview
Table 66. GSK HIV Antiretroviral Drug Product
Table 67. GSK Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 68. GSK Recent Development
Table 69. Bristol-Myers Squibb Company Company Detail
Table 70. Bristol-Myers Squibb Company Business Overview
Table 71. Bristol-Myers Squibb Company HIV Antiretroviral Drug Product
Table 72. Bristol-Myers Squibb Company Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 73. Bristol-Myers Squibb Company Recent Development
Table 74. Theratechnologies Inc. Company Detail
Table 75. Theratechnologies Inc. Business Overview
Table 76. Theratechnologies Inc. HIV Antiretroviral Drug Product
Table 77. Theratechnologies Inc. Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 78. Theratechnologies Inc. Recent Development
Table 79. Roche Holding AG Company Detail
Table 80. Roche Holding AG Business Overview
Table 81. Roche Holding AG HIV Antiretroviral Drug Product
Table 82. Roche Holding AG Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 83. Roche Holding AG Recent Development
Table 84. Teva Pharmaceuticals Company Detail
Table 85. Teva Pharmaceuticals Business Overview
Table 86. Teva Pharmaceuticals HIV Antiretroviral Drug Product
Table 87. Teva Pharmaceuticals Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 88. Teva Pharmaceuticals Recent Development
Table 89. Pfizer Company Detail
Table 90. Pfizer Business Overview
Table 91. Pfizer HIV Antiretroviral Drug Product
Table 92. Pfizer Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 93. Pfizer Recent Development
Table 94. Frontier Biotechnologies Company Detail
Table 95. Frontier Biotechnologies Business Overview
Table 96. Frontier Biotechnologies HIV Antiretroviral DrugProduct
Table 97. Frontier Biotechnologies Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 98. Frontier Biotechnologies Recent Development
Table 99. Shionogi Company Detail
Table 100. Shionogi Business Overview
Table 101. Shionogi HIV Antiretroviral DrugProduct
Table 102. Shionogi Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 103. Shionogi Recent Development
Table 104. Julphar Bangladesh Company Detail
Table 105. Julphar Bangladesh Business Overview
Table 106. Julphar Bangladesh HIV Antiretroviral DrugProduct
Table 107. Julphar Bangladesh Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 108. Julphar Bangladesh Recent Development
Table 109. Mylan Pharmaceuticals Inc. Company Detail
Table 110. Mylan Pharmaceuticals Inc. Business Overview
Table 111. Mylan Pharmaceuticals Inc. HIV Antiretroviral DrugProduct
Table 112. Mylan Pharmaceuticals Inc. Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 113. Mylan Pharmaceuticals Inc. Recent Development
Table 114. Genentech, Inc. Company Detail
Table 115. Genentech, Inc. Business Overview
Table 116. Genentech, Inc. HIV Antiretroviral DrugProduct
Table 117. Genentech, Inc. Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 118. Genentech, Inc. Recent Development
Table 119. Boehringer Ingelheim Company Detail
Table 120. Boehringer Ingelheim Business Overview
Table 121. Boehringer Ingelheim HIV Antiretroviral DrugProduct
Table 122. Boehringer Ingelheim Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 123. Boehringer Ingelheim Recent Development
Table 124. Cipla Company Detail
Table 125. Cipla Business Overview
Table 126. Cipla HIV Antiretroviral DrugProduct
Table 127. Cipla Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 128. Cipla Recent Development
Table 129. MSD Company Detail
Table 130. MSD Business Overview
Table 131. MSD HIV Antiretroviral DrugProduct
Table 132. MSD Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 133. MSD Recent Development
Table 134. Abbott Company Detail
Table 135. Abbott Business Overview
Table 136. Abbott HIV Antiretroviral DrugProduct
Table 137. Abbott Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 138. Abbott Recent Development
Table 139. Johnson & Johnson Company Detail
Table 140. Johnson & Johnson Business Overview
Table 141. Johnson & Johnson HIV Antiretroviral DrugProduct
Table 142. Johnson & Johnson Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 143. Johnson & Johnson Recent Development
Table 144. Biocon Limited Company Detail
Table 145. Biocon Limited Business Overview
Table 146. Biocon Limited HIV Antiretroviral DrugProduct
Table 147. Biocon Limited Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 148. Biocon Limited Recent Development
Table 149. Affine Formulations Limited Company Detail
Table 150. Affine Formulations Limited Business Overview
Table 151. Affine Formulations Limited HIV Antiretroviral DrugProduct
Table 152. Affine Formulations Limited Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 153. Affine Formulations Limited Recent Development
Table 154. IPCA Laboratories Company Detail
Table 155. IPCA Laboratories Business Overview
Table 156. IPCA Laboratories HIV Antiretroviral DrugProduct
Table 157. IPCA Laboratories Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 158. IPCA Laboratories Recent Development
Table 159. Natco Pharma Company Detail
Table 160. Natco Pharma Business Overview
Table 161. Natco Pharma HIV Antiretroviral DrugProduct
Table 162. Natco Pharma Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 163. Natco Pharma Recent Development
Table 164. Beacon Pharmaceuticals Company Detail
Table 165. Beacon Pharmaceuticals Business Overview
Table 166. Beacon Pharmaceuticals HIV Antiretroviral DrugProduct
Table 167. Beacon Pharmaceuticals Revenue in HIV Antiretroviral Drug Business (2017-2022) & (US$ Million)
Table 168. Beacon Pharmaceuticals Recent Development
Table 169. Research Programs/Design for This Report
Table 170. Key Data Information from Secondary Sources
Table 171. Key Data Information from Primary Sources
List of Figures
Figure 1. Global HIV Antiretroviral Drug Market Share by Type: 2021 VS 2028
Figure 2. Nucleoside Reverse Transcriptase Inhibitors Features
Figure 3. Non-Nucleoside Reverse Transcriptase Inhibitors Features
Figure 4. Protease Inhibitors Features
Figure 5. Fusion Inhibitors Features
Figure 6. Others Features
Figure 7. Global HIV Antiretroviral Drug Market Share by Application in 2021 & 2028
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Retail Pharmacies Case Studies
Figure 10. Online Pharmacies Case Studies
Figure 11. HIV Antiretroviral Drug Report Years Considered
Figure 12. Global HIV Antiretroviral Drug Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 13. Global HIV Antiretroviral Drug Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global HIV Antiretroviral Drug Market Share by Region: 2021 VS 2028
Figure 15. Global HIV Antiretroviral Drug Market Share by Players in 2021
Figure 16. Global Top HIV Antiretroviral Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HIV Antiretroviral Drug as of 2021)
Figure 17. The Top 10 and 5 Players Market Share by HIV Antiretroviral Drug Revenue in 2021
Figure 18. North America HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. North America HIV Antiretroviral Drug Market Share by Country (2017-2028)
Figure 20. United States HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Canada HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Europe HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Europe HIV Antiretroviral Drug Market Share by Country (2017-2028)
Figure 24. Germany HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. France HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. U.K. HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Italy HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Russia HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Nordic Countries HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Asia-Pacific HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Asia-Pacific HIV Antiretroviral Drug Market Share by Region (2017-2028)
Figure 32. China HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Japan HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. South Korea HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Southeast Asia HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. India HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Australia HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Latin America HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Latin America HIV Antiretroviral Drug Market Share by Country (2017-2028)
Figure 40. Mexico HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Brazil HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Middle East & Africa HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Middle East & Africa HIV Antiretroviral Drug Market Share by Country (2017-2028)
Figure 44. Turkey HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Saudi Arabia HIV Antiretroviral Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. ViiV Healthcare(GlaxoSmithKline) Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 47. Gilead Sciences Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 48. AbbVie Inc. Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 49. Merck & Co Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 50. GSK Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 51. Bristol-Myers Squibb Company Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 52. Theratechnologies Inc. Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 53. Roche Holding AG Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 54. Teva Pharmaceuticals Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 55. Pfizer Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 56. Frontier Biotechnologies Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 57. Shionogi Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 58. Julphar Bangladesh Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 59. Mylan Pharmaceuticals Inc. Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 60. Genentech, Inc. Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 61. Boehringer Ingelheim Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 62. Cipla Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 63. MSD Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 64. Abbott Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 65. Johnson & Johnson Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 66. Biocon Limited Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 67. Affine Formulations Limited Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 68. IPCA Laboratories Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 69. Natco Pharma Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 70. Beacon Pharmaceuticals Revenue Growth Rate in HIV Antiretroviral Drug Business (2017-2022)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
